Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual

Jun 27, 2021 10:00 AM - Jul 01, 2021 4:30 PM

DIA 2021 Global Annual Meeting

Risk-Based Quality Management and Monitoring: Practical Approaches

Session Chair(s)

Jean M. Mulinde, MD

Jean M. Mulinde, MD

Associate Director, Division of Clinical Compliance Evaluation, OSI

FDA, United States

In this session industry speakers will present their real-world experience with clinical trial oversight by discussing: 1) Case histories explaining audit and inspectional findings that identified significant compliance gaps, how findings were addressed, and proposals created to prevent similar findings in future studies, 2) Implementation of risk-based quality management and risk-based monitoring systems, 3) How the COVID-19 Pandemic has accelerated and transformed monitoring strategies, including use of centralized and remote monitoring strategies, and 4) Risk-based monitoring strategies used in a large COVID-19 Vaccine Trial and implications for successful implementation in future studies.

Learning Objective : Identify the importance of risk-based quality management and risk-based monitoring systems in clinical trial oversight; Describe the importance of good corrective and preventive action planning and how it functions as an integral part of your risk-based quality management system; Discuss how the COVID-19 Pandemic has accelerated innovation and spurred the use of risk-based monitoring strategies, including centralized statistical monitoring and remote monitoring strategies.

Speaker(s)

Kelly  Simpliciano, MS

Lessons Learned: Ensuring Electronic Systems Used in Clinical Trials Meet Data Integrity Requirements

Kelly Simpliciano, MS

Bristol-Myers Squibb Company, United States

Associate Director, Research Development Quality - Clinical Trials Systems & Aud

Mary  Arnould, BSN, MSN

Long-Term Site Monitoring Transformation Resulting from Critical Evaluation Brought About by COVID-19 Pandemic

Mary Arnould, BSN, MSN

Astellas, United States

Director, Clinical Science Operations

Crupa  Kurien

Driving a Culture of Quality Through Risk-Based Monitoring on the Mega-COVID19 Vaccine Trial: A Case Study

Crupa Kurien

Pfizer Inc, United States

Central Monitoring Manager, Risk Based Monitoring, Data Monitoring & Management,

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.